Hims & Hers Health (NYSE:HIMS) Shares Gap Down on Insider Selling

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) gapped down before the market opened on Wednesday following insider selling activity. The stock had previously closed at $31.05, but opened at $29.16. Hims & Hers Health shares last traded at $30.03, with a volume of 3,419,380 shares.

Specifically, insider Soleil Boughton sold 3,236 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $27.77, for a total value of $89,863.72. Following the completion of the sale, the insider now owns 170,285 shares of the company's stock, valued at $4,728,814.45. This trade represents a 1.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Melissa Baird sold 67,687 shares of the firm's stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $34.84, for a total value of $2,358,215.08. Following the sale, the chief operating officer now owns 751,243 shares of the company's stock, valued at $26,173,306.12. This represents a 8.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Remove Ads

Analyst Upgrades and Downgrades

HIMS has been the topic of a number of research analyst reports. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a report on Wednesday, April 2nd. BTIG Research started coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They issued a "buy" rating and a $35.00 target price for the company. Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a report on Tuesday, February 25th. Truist Financial boosted their target price on Hims & Hers Health from $24.00 to $39.00 and gave the stock a "hold" rating in a report on Wednesday, February 26th. Finally, Piper Sandler increased their price target on Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a research note on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $37.31.

Hims & Hers Health Stock Up 4.1 %

The company has a market capitalization of $6.01 billion, a price-to-earnings ratio of 61.52 and a beta of 1.65. The company has a 50-day moving average price of $39.82 and a 200-day moving average price of $30.03.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $481.14 million during the quarter, compared to analysts' expectations of $494.56 million. Equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently modified their holdings of the company. Crewe Advisors LLC acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at $28,000. Raleigh Capital Management Inc. raised its position in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 1,100 shares in the last quarter. Blume Capital Management Inc. lifted its stake in Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 600 shares during the period. Smartleaf Asset Management LLC boosted its holdings in Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC bought a new stake in shares of Hims & Hers Health in the 4th quarter valued at approximately $38,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.